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BSTRACT
 
Background
 
There are 500,000 cases per year of
visceral leishmaniasis, which occurs primarily in the
Indian subcontinent. Almost all untreated patients die,
and all the effective agents have been parenteral. Mil-
tefosine is an oral agent that has been shown in small
numbers of patients to have a favorable therapeutic
index for Indian visceral leishmaniasis. We performed
a clinical trial in India comparing miltefosine with the
most effective standard treatment, amphotericin B.
 
Methods
 
The study was a randomized, open-label
comparison, in which 299 patients 12 years of age or
older received orally administered miltefosine (50 or
100 mg [approximately 2.5 mg per kilogram of body
weight] daily for 28 days) and 99 patients received in-
travenously administered amphotericin B (1 mg per
kilogram every other day for a total of 15 injections).
 
Results
 
The groups were well matched in terms of
age, weight, proportion with previous failure of treat-
ment for leishmaniasis, parasitologic grade of splenic
aspirate, and splenomegaly. At the end of treatment,
splenic aspirates were obtained from 293 patients in
the miltefosine group and 98 patients in the ampho-
tericin B group. No parasites were identified, for an
initial cure rate of 100 percent. By six months after the
completion of treatment, 282 of the 299 patients in the
miltefosine group (94 percent [95 percent confidence
interval, 91 to 97]) and 96 of the 99 patients in the am-
photericin B group (97 percent) had not had a relapse;
these patients were classified as cured. Vomiting and
diarrhea, generally lasting one to two days, occurred
in 38 percent and 20 percent of the patients in the mil-
tefosine group, respectively. 
 
Conclusions
 
Oral miltefosine is an effective and
safe treatment for Indian visceral leishmaniasis. Mil-
tefosine may be particularly advantageous because
it can be administered orally. It may also be helpful in
regions where parasites are resistant to current agents.
(N Engl J Med 2002;347:1739-46.)
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ISCERAL leishmaniasis is caused by in-
fection of the visceral reticuloendothelial
system  by  leishmania  species  acquired
from sandfly bites. There are approximate-
ly 500,000 cases per year, with the majority in north-
eastern India, Nepal, and Bangladesh. Other areas
where visceral leishmaniasis is endemic include East
Africa, the littoral region of the Mediterranean, and
Brazil.
 
1
 
 The disease presents with fever, hepatospleno-
megaly, and pancytopenia. Almost all untreated pa-
tients die, generally because of intercurrent infection.
 
2,3
 
Both standard treatment and secondary treatment are
parenteral. Standard treatment consists of daily injec-
tions of pentavalent antimonial compounds for 28
days. In regions of India where there is a high frequen-
cy of resistance to antimony, amphotericin B in a dose
of 15 to 20 mg per kilogram of body weight is admin-
istered intravenously over a period of 30 to 40 days.
 
4
 
In patients who can pay for liposomal amphotericin B,
5 mg per kilogram is administered intravenously over
a period of five days.
 
5
 
Miltefosine (hexadecylphosphocholine) is an alkyl-
phosphocholine analogue that was originally devel-
oped as an antitumor agent but proved to be clinically
ineffective. Although the antileishmanial biochemical
mechanism remains unclear, miltefosine has good ef-
ficacy against leishmania in vitro
 
6
 
 and, with oral ad-
ministration, in animals.
 
7,8
 
 Within the past five years,
four phase 1–2 studies of the efficacy and tolerability
of oral miltefosine for Indian visceral leishmaniasis
have been reported.
 
9-12
 
 In the largest of these studies,
 
11
 
29 of 30 patients (97 percent) were cured with 100 mg
V
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of miltefosine per day (a mean of 2.5 mg of miltefo-
sine per kilogram per day) for 28 days.
We report the results of a phase 3 trial of miltefo-
sine. The objectives of the trial were to investigate the
efficacy and toxicity of miltefosine in larger numbers
of patients and in comparison with the efficacy and
toxicity of amphotericin B, the most potent clinical
antileishmanial agent currently in use.
 
METHODS
 
Study Design
 
We undertook a randomized, open-label, phase 3 trial comparing
oral miltefosine with the drug considered to represent the stand-
ard of care, intravenous amphotericin B. All authors participated
fully in the design of the study, had access to all study data, and
take responsibility for data analysis. The authors who are not em-
ployees of the sponsoring company had authority over the prep-
aration of the manuscript. The study was conducted in parallel at
three medical centers in Bihar, India. The ethics committees at the
three clinical centers approved the study protocol, the consent
forms, and all amendments. The initial visits of all study patients
were completed between July 1999 and July 2000.
 
Study Drug
 
Miltefosine (Zentaris) was administered orally for 28 days in a
dose as close to 2.5 mg per kilogram per day as was practicable. Pa-
tients weighing more than 25 kg received 100 mg daily (one 50-mg
capsule in the morning and one capsule in the evening after meals);
patients weighing 25 kg or less received 50 mg each morning. Am-
photericin B (Fungizone, Bristol-Myers Squibb) was administered
intravenously at a total dose of 15 mg per kilogram over a period
of 30 days (1 mg per kilogram every other day for a total of 15 in-
fusions). All patients were hospitalized during treatment, which was
observed.
 
Study Patients
 
Potentially eligible patients were 12 years of age or older with vis-
ceral leishmaniasis suspected on the basis of clinical presentation (fe-
ver, splenomegaly, and cytopenia) and diagnosed by the presence
of leishmania in splenic aspirates. Criteria for exclusion were a plate-
let count below 50,000 per cubic millimeter, a white-cell count be-
low 1000 per cubic millimeter, a hemoglobin concentration of less
than 6 g per deciliter, results on liver-function tests (serum aspartate
aminotransferase and alanine aminotransferase concentrations) more
than three times the upper limit of normal, a bilirubin concentra-
tion more than twice the upper limit of normal, serum creatinine
or blood urea nitrogen values more than 1.5 times the upper limit
of normal, other major medical illness including human immuno-
deficiency virus infection or severe malaria, pregnancy or lactation,
inability to maintain use of contraception for the period of treat-
ment plus two months, and previous therapy with amphotericin B.
 
Study Procedures
 
After written informed consent and data to evaluate eligibility
had been obtained, patients were centrally registered and randomly
assigned at each site to miltefosine or amphotericin therapy in a
3:1 ratio with the use of permuted blocks of four patients each.
Treatment was administered as described above. Weekly during
therapy, at the end of therapy (on day 28 for patients receiving mil-
tefosine and on day 30 for those receiving amphotericin), and six
months after the completion of therapy, patients were monitored
for subjectively reported adverse events, hematologic variables, se-
rum chemistry as on admission, and the size of the spleen as meas-
ured in centimeters below the left costal margin. Adverse events
were graded according to the Common Toxicity Criteria of the Na-
tional Cancer Institute.
 
13
 
 Parasitologic analysis of splenic aspirates
was performed at the end of therapy and was repeated at six-month
follow-up in patients with signs and symptoms suggestive of vis-
ceral leishmaniasis. Male patients of reproductive age were queried
a median of 23 months (range, 11 to 31) after the completion of
therapy regarding the numbers and health of children born to their
sexual partners.
 
Efficacy End Points
 
The density of parasites was graded on a log scale from 0 (no
parasites per 1000 fields of 1000¬ power) to 6 (>100 parasites
per field).
 
14
 
 Cure was defined as an absence of parasites at the end
of therapy or a parasite density of 1 with no parasites on repeated
smear one month later (initial cure) plus no relapse during the six
months of follow-up. Relapse was defined by signs or symptoms
suggestive of leishmaniasis and appearing after an initial cure, fol-
lowed by a positive test for leishmania in a splenic aspirate. Treat-
ment failure was defined as either the lack of initial cure or relapse.
 
Statistical Analysis
 
The end point of this trial designed to assess noninferiority was
the proportion of patients with a final cure. The considerations
for the sample size and the confirmatory analysis were determined
on the basis of the restricted maximum-likelihood estimation of the
variance of the test statistic,
 
15
 
 with a one-sided alpha of 0.025, a
power of 0.80, a margin of noninferiority of 15 percent, assumed
cure rates for miltefosine of 88 to 92 percent and for amphotericin
of 94 to 98 percent, and a ratio of 3:1 for the random assignment
of patients to miltefosine and amphotericin. The number of patients
required overall was 400.
 
RESULTS
 
Base-Line Characteristics of the Patients
 
Base-line characteristics of the patients are summa-
rized in Table 1. Approximately 10 percent of screened
patients with visceral leishmaniasis were excluded
from the trial because they had severe disease (data not
shown). Ultimately, 299 patients received miltefosine,
and 99 patients received amphotericin.
Except for sex, the base-line characteristics were
similar in the two treatment groups. The mean par-
asite density was approximately grade 3 (defined as
1 to 10 parasites per 10 fields); mean splenomegaly
was 6.9 cm. Most patients had moderate pancytope-
nia. The serum aspartate aminotransferase and alanine
aminotransferase concentrations were above the up-
per limit of normal in 82 percent of the patients in the
miltefosine group and 77 percent of those in the am-
photericin group. Twenty-eight percent of patients
had previously been treated with pentavalent anti-
monial compounds.
 
Efficacy
 
The efficacy of the treatments is shown in Table 2.
At the end of the course of treatment, splenic aspirates
were obtained from 293 of the 299 patients in the mil-
tefosine group and 98 of the 99 patients in the ampho-
tericin group. All were parasitologically negative. Thus,
for both treatment groups, the rate of initial cure was
100 percent among patients for whom parasitologic
The New England Journal of Medicine 
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analysis was performed. In both groups, at the end
of therapy, the mean size of the spleen below the cos-
tal margin had decreased dramatically to 1.0 cm.
At the six-month follow-up visit, 291 patients in the
miltefosine group and 96 patients in the amphotericin
group were evaluated. A total of 97 patients in the mil-
tefosine group and 16 in the amphotericin group had
symptoms that were potentially indicative of leishma-
niasis. In 86 of these 113 patients, causes other than
leishmaniasis were identified. The 27 patients in whom
relapse of leishmaniasis could not be ruled out clini-
cally were all in the miltefosine group. In most of these
 
*Plus–minus values are means ±SD. To convert values for serum creatinine to milligrams per deciliter, divide by 88.4.
To convert values for blood urea nitrogen to millimoles per liter, multiply by 0.357.
†Data for this patient were analyzed with those for the amphotericin group.
‡Density ranges from 0 to 6, with higher scores indicating greater splenic parasite load.
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No. assigned to group
No. who did not receive drug
No. with randomization error†
301
1
1
99
1
0
No. treated with drug 299 99
Sex — no. (%)
Male
Female
211 (71)
88 (29)
58 (59)
41 (41)
Age — yr 26±13 26±12
Weight — kg 39±10 38±12
No previous treatment prescribed
for leishmania — no. (%)
214 (72) 71 (72)
Parasite density‡ 2.9±1.0 2.9±1.1
Splenomegaly — cm below left costal margin 6.9±4.3 6.9±4.3
Laboratory values
White cells — no./mm
 
3
 
Platelets — no./mm
 
3
 
Hemoglobin — g/dl
Serum aspartate aminotransferase — U/liter
Serum alanine aminotransferase — U/liter
Serum creatinine — µmol/liter
Blood urea nitrogen — mg/dl
Corrected QT interval — msec
3350±1670
122,000±68,000
8.0±1.5
58±25
47±31
81±24
12±4
348±40
3760±1880
117,000±50,000
8.4±1.7
58±26
45±30
78±23
12±4
341±38
>4,000
>150,000
>13.0
<35
<56
<124
<21
<431
*CI denotes confidence interval.
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(N=299)
A
 
MPHOTERICIN
 
G
 
ROUP
 
(N=99)
 
At completion of therapy
 
Parasitologic cure — no. (% [95% CI]) 293 (98 [96–99]) 98 (99 [95–100])
Difference between cure rate with miltefosine
and cure rate with amphotericin —
% (lower 95% confidence limit)
¡1.0 (¡3.5)
Not assessed — no. (%) 6 (2) 1 (1)
 
At 6 mo
 
Final cure — no. (% [95% CI]) 282 (94 [91–97]) 96 (97 [91–99])
Difference between cure rate with miltefosine
and cure rate with amphotericin —
% (lower 95% confidence limit)
¡2.7 (¡6.6)
Treatment failure (relapse) — no. (%) 9 (3) 0
Not assessed — no. (%) 8 (3) 3 (3)
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patients, the abnormality seen at that time was anemia.
Splenic aspiration was performed in these 27 patients,
and aspirates from 9 patients tested positive for leish-
maniasis. Thus, there were nine patients in the milte-
fosine group (3 percent) and no patients in the ampho-
tericin group with a relapse of visceral leishmaniasis
after therapy. Spleens were not palpable in 262 of the
291 patients in the miltefosine group evaluated at six
months (90 percent) or in 88 of the 96 patients in the
amphotericin group evaluated at that time (92 per-
cent). There were eight patients in the miltefosine
group and three patients in the amphotericin group
who could not be assessed at the six-month follow-
up. The cure rate for miltefosine was therefore 282 of
299, or 94 percent, as compared with 96 of 99, or 97
percent, for amphotericin. Among the patients who
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Symptoms
 
Vomiting — no. (%)
Total
Duration
1–2 days
3–4 days
>4 days
Common Toxicity Criteria grade†
1
2
113 (38)
82 (27)
23 (8)
8 (3)
79 (26)
34 (11)
20 (20)
15 (15)
3 (3)
2 (2)
16 (16)
4 (4)
Diarrhea — no. (%)
Total
Duration
1–2 days
3–4 days
>4 days
Common Toxicity Criteria grade‡
1
2
4
61 (20)
46 (15)
14 (5)
1 (<1)
48 (16)
12 (4)
1 (<1)
6 (6)
4 (4)
1 (1)
1 (1)
3 (3)
3 (3)
0
Rigors — no. (%)
Total
Duration
1–2 days
3–4 days
5–16 days
Severity
Mild or brief
Pronounced or prolonged
1 (<1)
1 (<1)
0
0
1 (<1)
0
90 (90)
13 (13)
14 (14)
63 (64)
54 (54)
36 (36)
 
Laboratory values§
 
Serum aspartate aminotransferase
Mean change from base line — U/liter (%)
Wk 1
Wk 2
At completion of therapy
At 6 mo
+10 (17)
¡1 (¡2)
¡5 (¡9)
¡16 (¡28)
+0.7 (1)
¡13 (¡22)
¡19 (¡33)
¡1 (¡2)
Patients with increases — no. (%)¶
Grade 1
Grade 2
Grade 3
91 (30)
70 (23)
16 (5)
28 (28)
16 (16)
3 (3)
Serum alanine aminotransferase
Mean change from base line — U/liter (%)
Wk 1
Wk 2
At completion of therapy
At 6 mo
+0.7 (1)
+5.5 (12)
+6 (13)
¡5 (¡11)
+8 (18)
¡2 (¡4)
¡10 (¡22)
¡3 (¡7)
Patients with increases — no. (%)¶
Grade 1
Grade 2
Grade 3
133 (44)
21 (7)
1 (<1)
26 (26)
2 (2)
1 (1)
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were evaluated at six months, the cure rate was 282
of 291 (97 percent) for miltefosine and 96 of 96 (100
percent) for amphotericin B.
 
Patients with Relapses
 
The nine patients who had a relapse did not differ
from the cured patients in terms of the following base-
line characteristics. For the patients with relapse, the
mean values were as follows: age, 36 years; extension
of the spleen below the costal margin, 6.7 cm; parasite
density, 2.1; proportion that had received previous
treatment, 67 percent; and daily dose, 2.3 mg per kil-
ogram.
 
Cure Rate among Patients with Premature 
Discontinuation of Drug Treatment
 
Of the nine patients in the miltefosine group in
whom drug treatment was discontinued prematurely,
one withdrew from the study and eight discontinued
the drug because of a lack of tolerance or intercurrent
disease. Of these eight patients, four did not return
for the six-month follow-up. Of the other four pa-
tients, three had a final cure: one who discontinued
treatment after 14 days because of a high bilirubin
concentration, one who discontinued treatment after
6 days because of Stevens–Johnson syndrome, and
one who discontinued treatment after day 21 because
 
*To convert values for serum creatinine to milligrams per deciliter, divide by 88.4. To convert values
for blood urea nitrogen to millimoles per liter, multiply by 0.357.
†For vomiting, a Common Toxicity Criteria grade of 1 signifies 1 episode per day, grade 2 signifies
2 to 5 episodes per day, grade 3 signifies 6 to 10 episodes per day, and grade 4 signifies more than
10 episodes per day.
‡For diarrhea, a Common Toxicity Criteria grade of 1 signifies an increase of 2 to 3 stools per day,
grade 2 an increase of 4 to 6 stools per day, grade 3 an increase of 7 to 9 stools per day, and grade
4 an increase of 10 or more stools per day.
§Base-line values are shown in Table 1.
¶For aspartate aminotransferase and alanine aminotransferase, Common Toxicity Criteria grade 1
signifies values at least 2.5 times the upper limit of normal, grade 2 values 2.6 to 5.0 times the upper
limit of normal, and grade 3 values 5.1 to 20 times the upper limit of normal.
¿For creatinine, Common Toxicity Criteria grade 1 signifies values less than 1.5 times the upper
limit of normal, grade 2 values 1.5 to 3.0 times the upper limit of normal, and grade 3 values 3.1 to
6.0 times the upper limit of normal.
**For blood urea nitrogen, Common Toxicity Criteria grade 1 signifies values less than 1.5 times
the upper limit of normal, grade 2 values 1.5 to 2.4 times the upper limit of normal, and grade 3
values more than 2.4 times the upper limit of normal.
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(N=99)
Laboratory values§ (continued)
Serum creatinine
Mean change from base line — µmol/liter (%)
Wk 1
Wk 2
At completion of therapy
At 6 mo
¡1 (¡1)
¡3 (¡4)
¡2 (¡2)
+0.3 (0)
+27 (35)
+21 (27)
+17 (22)
+4 (5)
Patients with increases — no. (%)¿
Grade 1
Grade 2
Grade 3
20 (7)
6 (2)
2 (1)
33 (33)
9 (9)
0
Blood urea nitrogen
Mean change from base line — mg/dl
Wk 1
At completion of therapy
At 6 mo
¡0.6 (¡5)
0.9 (8)
¡0.5 (¡4)
+5.0 (42)
+5.0 (42)
+0.5 (4)
Patients with increases — no. (%)**
Grade 1
Grade 2
Grade 3
20 (7)
6 (2)
4 (1)
30 (30)
10 (10)
3 (3)
Corrected QT interval on electrocardiography
Mean change from base line — msec (%)
Wk 1
At completion of therapy
+14 (4)
+18 (5)
+39 (11)
+31 (9)
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of bleeding hemorrhoids. The fourth patient, who
discontinued treatment after 11 days because of ar-
thritis and rash, had a relapse.
Cure Rate among Patients with Previous Therapy
for Leishmaniasis
In the miltefosine group, the cure rate among pa-
tients who had previously been treated was identical
to the cure rate among patients who had not (94
percent).
Toxic Effects
Signs and symptoms of toxic effects are summa-
rized in Table 3. The percentage of patients in the mil-
tefosine group who had vomiting or diarrhea was
higher than that in the amphotericin group. Howev-
er, such effects were mild (grade 1 or 2) in almost all
affected patients in both groups, and the number of
patients taking antiemetic or antinausea agents was
3 to 4 percent in both groups. One patient in the mil-
tefosine group discontinued treatment because of gas-
trointestinal intolerance. Ninety percent of the patients
in the amphotericin group had rigors associated with
fever, whereas only one patient in the miltefosine
group had this symptom.
Laboratory Variables
The results of laboratory tests are summarized in
Table 3. In the miltefosine group, the mean serum
aspartate aminotransferase concentration increased by
17 percent during the first week of therapy, before
falling to the pretreatment values during the second
week and then decreasing further as disease resolved.
The mean serum alanine aminotransferase concentra-
tion increased by 12 percent during the second week
before regressing by the six-month follow-up visit.
There was a grade 3 elevation in the serum aspartate
aminotransferase concentration in 16 patients in the
miltefosine group (5 percent), but therapy was not
terminated prematurely in any patient because of liver-
enzyme values. In the amphotericin group, 3 percent
of patients had grade 3 elevations.
Mean values on renal-function tests did not change
significantly in the miltefosine group. However, 16
percent of patients had grade 1, 2, or 3 increases in
blood urea nitrogen values, serum creatinine concen-
trations, or both. There were five patients in the mil-
tefosine group (2 percent) with grade 3 elevations:
one patient had an elevated creatinine value of 1.63 mg
per deciliter (144 µmol per liter) before treatment,
which peaked at 5.00 mg per deciliter (442 µmol per
liter) during therapy; three patients had concurrent
administration of albendazole and diclofenac, concur-
rent malaria, or concurrent meningitis. The fifth pa-
tient had no explanation other than miltefosine treat-
ment for a grade 2 increase in serum creatinine and a
grade 3 increase in blood urea nitrogen on day 21.
The creatinine and blood urea nitrogen concentrations
partially regressed on day 28 despite continued ther-
apy. In the amphotericin group, 60 percent of patients
had elevated blood urea nitrogen or creatinine levels
during therapy.
Hemoglobin, leukocytes, and platelets increased
steadily in both treatment groups (data not shown),
in accord with the resolution of disease. Electrocardi-
ography (Table 3) and ophthalmologic examination in
both treatment groups did not show clinically relevant
abnormalities.
Reproductive Capacity
In rats, high-dose miltefosine impairs male repro-
ductive capacity. In this study, we tracked the number
of live and healthy infants born to sexual partners of
male patients of reproductive age who did not use con-
traception. In the miltefosine group, there were 48
live infants with no known congenital abnormalities
born to the partners of 80 such male patients (0.6
birth per patient). By comparison, in the amphotericin
group, there were 12 live infants with no congenital
abnormalities born to the partners of 20 such male
patients (0.6 birth per patient).
Serious and Other Adverse Events
Six patients in the miltefosine group and one patient
in the amphotericin group had serious adverse events.
In the miltefosine group, these events included con-
vulsion due to a cranial cyst (in two patients), abrupt
anemia due to bleeding hemorrhoids (in one patient),
Plasmodium vivax malaria (in one patient), gram-neg-
ative meningitis that resulted in death two days later
(in one patient), and the Stevens–Johnson syndrome
(in one patient). Only the Stevens–Johnson syndrome
was thought to be attributable to drug treatment. The
patient was a 12-year-old boy who received 50 mg
of miltefosine (2.8 mg per kilogram) daily. On day
6 of therapy, rash was seen, and treatment was stopped.
Bullae, necrosis, and peeling skin were apparent on day
7; dexamethasone therapy was started. Fever abated
on day 8. The patient was afebrile on day 12, and le-
sions healed by approximately day 20. As noted above,
this patient was cured.
Other Discontinuations Due to Adverse Events
in the Miltefosine Group
The four patients in the miltefosine group (1 per-
cent) who discontinued therapy because of probable
drug intolerance were as follows. One patient had ar-
thritis and an allergic skin rash on day 9 and stopped
taking miltefosine the next day. One patient, who was
receiving concomitant treatment with metronidazole
for giardia cysts, had grade 4 diarrhea requiring par-
enteral fluids after two weeks of miltefosine therapy.
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Miltefosine was stopped at that point. One patient had
an increase in the bilirubin concentration on day 14
of miltefosine treatment, at which time miltefosine was
stopped. The fourth patient had grade 4 thrombocy-
topenia, epistaxis, increases in aspartate aminotransfer-
ase, and an increase in blood urea nitrogen. Therapy
was stopped on day 7.
DISCUSSION
This controlled trial shows that oral miltefosine is
an effective and safe treatment for Indian visceral leish-
maniasis in immunocompetent patients 12 years of age
or older. To our knowledge, this is the largest chemo-
therapy study performed according to the Good Clin-
ical Practice guidelines16 for any form of leishmania-
sis. Of the 398 patients who presented with moderate
visceral leishmaniasis (kala-azar), 299 were treated
with oral miltefosine for 28 days at a dose of approx-
imately 2.5 mg per kilogram per day. At the end of
therapy, none of the 293 patients in whom parasito-
logic analysis was performed had evidence of parasites,
and all were considered to be cured. At the six-month
follow-up, 291 patients were evaluated; 9 had para-
sites on splenic aspiration. Thus, the six-month cure
rate was 282 of 299 (94 percent).
Vomiting and diarrhea occurred in 38 percent and
20 percent, respectively, of patients receiving milte-
fosine. Approximately three quarters of the gastroin-
testinal events lasted one to two days per patient and
occurred once on each of these days. The mean serum
aspartate aminotransferase and alanine aminotransfer-
ase concentrations increased by approximately 15 per-
cent during the first and second weeks, respectively,
before normalizing by the end of week 2 and by the
six-month follow-up visit, respectively. The transient
elevation in liver enzymes during treatment is attrib-
uted to a moderate effect of miltefosine on hepato-
cytes. Mean results on renal-function tests were not
substantially altered by miltefosine, although 16 per-
cent of individual patients had mild-to-moderate ele-
vations of serum creatinine, blood urea nitrogen, or
both. Results on electrocardiography and ophthalmic
examination and male reproductive capacity were not
significantly altered.
Therapeutic agents may be compared with respect
to efficacy, tolerance, and feasibility and cost of admin-
istration. Standard therapy for visceral leishmaniasis is
pentavalent antimony or, in regions with a high prev-
alence of antimony resistance such as the one where
this study was conducted, amphotericin B. Antimoni-
al compounds have the disadvantages of both toxicity
and clinical resistance in at least 40 percent of cases in
certain regions where they have been in use for a long
time.17 Common adverse effects are myalgia, arthral-
gia, anorexia, hyperamylasemia, and increases in liver
enzymes. Uncommon adverse effects are substantial
decreases in the numbers of leukocytes and platelets
and death due to arrhythmia.2
For comparison with miltefosine, amphotericin B
was tested in 99 patients in this phase 3 study. A total
of 97 percent of patients who received amphotericin
were cured, but the well-known adverse effects of fe-
ver or chills and elevations on renal-function tests oc-
curred in 90 percent and 60 percent of patients, re-
spectively. Liposomal amphotericin B is highly effective
and well tolerated, but its cost is a barrier to wide-
spread use even in developed countries. Pentamidine
has been used in antimony-resistant cases, but toler-
ance is problematic, and resistance is now evident.18,19
Paromomycin is still being evaluated.20
Given our demonstration of a cure rate of 94 per-
cent in a large number of patients 12 years of age or
older, the efficacy of miltefosine compares well with
that of all other agents, including amphotericin B and
liposomal amphotericin B. The side effects of milte-
fosine are generally tolerable and compare favorably
with those of all agents other than liposomal ampho-
tericin B. Miltefosine has toxic effects on reproductive
capacity in female animals, and strict contraception
must be practiced by female patients during the pe-
riod of treatment and for two months after therapy.
The risk of fetal abnormalities means that the distri-
bution of drugs must be carefully controlled in coun-
tries where leishmaniasis is endemic.
The striking advantage of miltefosine is that it is ad-
ministered orally. Miltefosine is now registered in In-
dia (under the trade name Impavido [Zentaris]) for
patients 2 years of age or older on the basis of other
studies in patients in India 2 to 11 years of age that
have been completed but not reported. However, be-
cause the heaviest patient in Indian studies weighed
only 67 kg, dose recommendations for patients with
higher weights have not yet been specified. Future
trials should show whether this drug will be useful
against visceral leishmaniasis in other regions and in
populations for which parenteral agents are not at-
tractive.
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